Bayer Reshuffles Leadership in Pharma and Consumer Health as Stock Struggles for Traction

Bayer quietly reshuffles leadership in radiology and consumer health, while shares trade below key averages and Supreme Court glyphosate case looms.

The German pharmaceutical and life sciences group has quietly rolled out a series of management changes across two of its core divisions, appointing a new head of radiology and simultaneously refreshing the marketing leadership of its over-the-counter business. The moves come as the stock trades below key technical levels and the company braces for a potentially landmark US Supreme Court ruling in the glyphosate litigation.

Dr. Jost Reinhard, until recently the group’s head of investor relations, will take over the radiology unit within the Pharmaceuticals division on 1 August 2026. He replaces Nelson Ambrogio, who was shifted to lead Bayer’s US pharmaceuticals business in May. Reinhard reports directly to pharma board member Stefan Oelrich. His background is unusually broad for the role: he started in R&D at Schering in 2001, later held commercial leadership positions in Australia, Poland and France, and ran the cell and gene therapy unit in Boston before returning to Leverkusen to manage relations with global capital markets. The radiology business — encompassing contrast media, injectors for CT, MRI, X-ray and PET, as well as diagnostic imaging software — is considered one of the growth pillars of Bayer’s pharma portfolio.

Alongside the radiology appointment, Bayer is overhauling the top ranks of its Consumer Health division. Divisional chief Julio Triana has brought in Samantha Avivi as global head of marketing, based in New Jersey, where she will oversee brand building and consumer strategy. Two other key roles are also being filled: a new data chief to harness artificial intelligence and analytics, and a new president for the US market, replacing Ambrogio after his earlier transfer. The reorganisation is part of an internal initiative called “Road to Billions”, aimed at accelerating growth in over-the-counter remedies for pain and colds through data-driven decision-making. Consumer Health, together with Pharmaceuticals and Crop Science, forms one of the group’s three pillars.

The financial backdrop for these changes is uneven. In the first quarter of 2026, Bayer’s Pharmaceuticals division posted revenue of €4.2 billion, but EBITDA before special items fell 7.5% year-on-year to €1.2 billion. Group-level results were stronger: total revenue rose 4.1% on a currency-adjusted basis to €13.4 billion, with EBITDA before special items climbing 9.0%. The group employed roughly 88,000 people last year and generated turnover of around €45.6 billion.

Cash flow remains a sore spot. Free cash flow in the first quarter was negative €2.3 billion, which Bayer attributed to payments related to legal settlements. That pressure is unlikely to ease quickly, and the new leadership teams in both pharma and consumer health will be expected to improve operational cash generation.

Meanwhile, Bayer shares continue to tread water. The stock closed at €35.19, nearly 8% below its 50-day moving average of €38.23, and has fallen about 7.5% since the start of the year. A separate session saw the shares trade at €35.29, dipping just below the 200-day average. The technical picture remains fragile as investors weigh internal restructuring against external legal risk.

That risk centres on the “Durnell” case, now before the US Supreme Court. The justices are examining whether individual states can require their own warning labels on glyphosate products. A ruling in Bayer’s favour would sharply reduce the company’s remaining liability exposure and could trigger a re-rating of the equity. For now, the market is waiting — and so are Reinhard, Avivi and the rest of the newly assembled management team.